[MNK] Mallinckrodt plc

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NYSE

The data is delayed by 15 minutes.

 

Price: 53.18 Change: 1.16 (2.23%)
Ext. hours: 53 Change: -0.18 (-0.34%)

chart MNK

Refresh chart

Strongest Trends Summary For MNK

MNK is in the medium-term up 34% in 3 months and down -31% in 7 months. In the long-term down -86% below S&P in 6 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Mallinckrodt public limited company develops, manufactures, markets, and distributes specialty pharmaceutical products and medical imaging agents worldwide. The company operates through two segments, Specialty Pharmaceuticals and Global Medical Imaging. The Specialty Pharmaceuticals segment provides Acthar, an injectable biopharmaceutical drug for use in various indications, including neurology, rheumatology, nephrology, and pulmonology; Ofirmev and Xartemis XR for pain indications; EXALGO extended-release tablets to treat chronic pain; and GABLOFEN injections for use in the management of spasticity of cerebral or spinal origin. It also offers generics and active pharmaceutical ingredients (API), such as hydrocodone and hydrocodone-containing tablets, oxycodone and oxycodone-containing tablets, and methylphenidate HCl extended-release tablets, as well as biologics, medicinal opioids, synthetic controlled substances, acetaminophen products, and other active ingredients. The Global Medical Imaging segment provi

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 39.32% Sales Growth - Q/Q5.03% P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-1.44% ROE-3.57% ROI-1.9%
Current Ratio2.86 Quick Ratio2.41 Long Term Debt/Equity2.75 Debt Ratio0.15
Gross Margin50.09% Operating Margin-4.3% Net Profit Margin-5.75% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities40.6 M Cash From Investing Activities-53 M Cash From Operating Activities365.5 M Gross Profit488.5 M
Net Profit98.8 M Operating Profit95.2 M Total Assets12.81 B Total Current Assets2.22 B
Total Current Liabilities775.7 M Total Debt3.99 B Total Liabilities7.63 B Total Revenue909.9 M
Technical Data
High 52 week36.08 Low 52 week11.99 Last close22.46 Last change1.22%
RSI74.56 Average true range0.75 Beta1.34 Volume1.2 M
Simple moving average 20 days8.28% Simple moving average 50 days10.45% Simple moving average 200 days-3.26%
Performance Data
Performance Week5.69% Performance Month30.51% Performance Quart-16.19% Performance Half-7.07%
Performance Year30.13% Performance Year-to-date42.15% Volatility daily2.21% Volatility weekly4.94%
Volatility monthly10.12% Volatility yearly35.05% Relative Volume178.31% Average Volume2.26 M
New High New Low

News

2019-03-22 09:30:01 | Is Mallinckrodt public limited MNK Stock Outpacing Its Medical Peers This Year?

2019-03-22 09:10:01 | Is Mallinckrodt MNK Stock Undervalued Right Now?

2019-03-21 17:45:09 | Mallinckrodt MNK Gains But Lags Market: What You Should Know

2019-03-19 11:51:03 | Allergan's Anti-Infective Gets FDA Nod for Pediatric Patients

2019-03-19 11:49:03 | Top Ranked Value Stocks to Buy for March 19th

2019-03-18 06:45:00 | Bryan Reasons Joins Mallinckrodt as the Company's Chief Financial Officer CFO

2019-03-15 06:55:00 | Mallinckrodt's Hobart, N.Y. and St. Louis, Mo. Sites Recognized as 2019 Manufacturing Leadership Award Winners

2019-03-13 06:30:00 | Look Out for Big Pharma Credit Downgrades This Year

2019-03-12 09:55:01 | Is Mallinckrodt MNK a Great Stock for Value Investors?

2019-03-11 13:13:34 | Opioid litigation concerns weigh on pharmaceutical loan borrowers

2019-03-11 10:31:05 | What Could Drive Mallinckrodt’s Growth in Fiscal 2019

2019-03-11 09:55:01 | Add These 6 Low P/B Stocks to Your Portfolio in March

2019-03-11 09:00:57 | Comparing Endo’s and Mallinckrodt’s Gross Margin Forecasts

2019-03-11 07:31:56 | How Endo’s and Mallinckrodt’s Expense Control Stacks Up

2019-03-08 14:40:02 | Endo International’s and Mallinckrodt’s EPS Growth Expectations

2019-03-08 13:10:02 | Comparing Endo’s and Mallinckrodt’s Revenue Forecasts

2019-03-08 11:37:59 | Analysts’ Views on Endo International and Mallinckrodt

2019-03-08 09:30:02 | MNK vs. AMPH: Which Stock Should Value Investors Buy Now?

2019-03-06 09:15:02 | Stocks Get Stuck Waiting for Trade Deal

2019-03-05 11:16:44 | OxyContin Maker Purdue Pharma's Legal Entanglement, Explained

2019-03-04 06:55:00 | Mallinckrodt Presents New Data on Real-World Resource Utilization Associated with Continuation of Systemic Treatment among Patients with Cutaneous T-cell Lymphoma at 2019 American Academy of Dermatology Annual Meeting

2019-03-01 14:22:33 | New Enterprise Associates is raising its biggest fund yet. Here's how much it's going for.

2019-02-27 15:30:08 | Mallinckrodt MNK Rallies as Earnings Beat Estimates in Q4

2019-02-27 08:32:01 | Implied Volatility Surging for Mallinckrodt MNK Stock Options

2019-02-26 16:11:09 | This Pharma Stock Is Making A Bullish Run After Crushing Earnings Views

2019-02-26 15:51:59 | Edited Transcript of MNK earnings conference call or presentation 26-Feb-19 1:30pm GMT

2019-02-26 15:11:10 | Mallinckrodt PLC MNK Q4 2018 Earnings Conference Call Transcript

2019-02-26 14:30:00 | Here's Why Mallinckrodt Jumped as Much as 26.8% Today

2019-02-26 11:18:00 | Mallinckrodt stock up 14% on earnings beat

2019-02-26 07:58:30 | Stocks making the biggest moves premarket: Home Depot, Caterpillar, Tesla & more

2019-02-26 06:05:00 | Mallinckrodt plc Reports Strong Fourth Quarter and Total Company 2018 Results, Announces 2019 Guidance and Strategic Priorities

2019-02-25 13:41:02 | Mallinckrodt's Q4 Earnings Preview

2019-02-25 09:00:00 | Mallinckrodt Announces Extracorporeal Photopheresis ECP Research Collaboration Agreement With Transimmune AG

2019-02-25 06:55:00 | Mallinckrodt Announces Extracorporeal Photopheresis Research Collaboration Agreement With Transimmune AG

2019-02-22 09:21:02 | What's in the Cards for Perrigo PRGO This Earnings Season?

2019-02-22 09:06:02 | Zacks.com featured highlights include: Mallinckrodt, Dell, American Axle, Daqo and General Motors

2019-02-21 09:15:02 | Another Round of Slight Gains Amid Choppy Session

2019-02-21 07:21:12 | 6 Low Price-to-Book Stocks for Value Investors

2019-02-21 03:00:00 | Mallinckrodt Announces Interim Analysis Results for TherakosR Platform Phase 3 Clinical Trial in Treatment of Pediatric Patients with Steroid Refractory Acute Graft-versus-Host Disease

2019-02-20 15:09:08 | Mylan MYL to Report Q4 Earnings: What's in the Offing?

2019-02-20 06:55:00 | Mallinckrodt Announces Interim Analysis Results for Therakos® Platform Phase 3 Clinical Trial in Treatment of Pediatric Patients with Steroid Refractory Acute Graft-versus-Host Disease

2019-02-19 17:47:10 | Generic-Drugs Outlook: Price Erosion to Hurt Near-Term Prospects

2019-02-18 08:16:01 | What's in the Cards for Amarin AMRN This Earnings Season?

2019-02-15 16:08:09 | What's in the Cards for Bausch Health BHC Q4 Earnings?

2019-02-13 09:30:02 | MNK vs. AMPH: Which Stock Should Value Investors Buy Now?

2019-02-12 06:55:00 | Mallinckrodt To Present At Barclays Global Healthcare Conference

2019-02-11 15:58:08 | Is a Disappointment in Store for Incyte INCY Q4 Earnings?

2019-02-08 17:13:10 | Teva TEVA to Report Q4 Earnings: What's in the Cards?

2019-02-08 16:56:09 | Tilray TLRY to Report Q4 Earnings: What's in the Cards?

2019-02-08 08:03:15 | See what the IHS Markit Score report has to say about Mallinckrodt Plc.